Abstract:Abstract: Biphasic calcium phosphate (BCP) cement, consisting of an α-tricalcium phosphate-tetracalcium phosphate as the only solid phase and a calcium phosphate solution (Ca-P soln) as the liquid phase, was recently reported. The BCP cement provided suffi cient handling and physical properties for clinical uses. Objective of this study was to evaluate the BCP cement when used for repairing artificially created bone defects in rat calvaria. The sample of BCP cement was prepared by mixing BCP powder with Ca-P soln at P/L of 3.0. A commercially available calcium phosphate cement, Biopex-R, was used as a positive control. Surgically created bone defects were fi lled with the BCP cement or the control cement. A defect with no fi lling material was used as a negative control. At 0 and 8 weeks after surgery, X-ray micro-CT image for each surgical site was taken. At 8 weeks after the surgery, the animals were sacrifi ced, and biopsies were obtained. Subsequently, the sections were subjected to HE and TRAP staining and examined under a microscope. After microscopic examination, computer-assisted histometric measurements of newly formed bone (NB) were performed using NIH image analysis. Defect closure (DC) was determined by measuring the distance between defect margin and new bone margin, and was expressed as a percentage of total defect width. The BCP cement kept original graft shape, and defects fi lled with the cement were mostly closed by NB. The control cement inadequately maintained original graft shape, and defects fi lled with the control cement were partially closed by NB. The negative control showed almost no bone formation in the defects. The DC rate of the BCP cement exhibited apparently larger than that of the control cement (p<0.05). These results were also confi rmed by fl uorescent labelling analysis and X-ray micro-CT observations. The results indicated that the BCP cement had osteoconductive potential for bone defects.
Introduction
All current commercial calcium phosphate cements (CPC), consist of two or more calcium phosphates, calcium-containing or phosphatecontaining compounds as the solid phase and a sodium phosphate solution or organic acid, such as citric, tartaric, malic or lactic acid as the liquid phase. Most of CPC's powder compounds [1] [2] [3] [4] , which need to be manufactured separately and ground to the required particle size distribution, are then thoroughly blended to produce a homogeneous mixture. Such a mixture typically exhibited a bi-modal size distribution. Some cement powders even require poly-modal size distributions. Therefore, the handling, hardening, mechanical, and most importantly in vivo properties of CPC products depend strongly on the composition and size distributions of the CPC powders. As a result, these CPCs are diffi cult to manufacture to the standards required by the regulatory authorities, leading to high production costs. The CPC, which powder was consisted of an α-tricalcium phosphate (α-TCP)-tetracalcium phosphate (TTCP) at different molar ratio and liquid consisted of a sodium dihydrogen phosphate, was previously reported 5) . However, the cement took 14 to 28 days to cure, and showed insufficient physical strength for clinical use.
Biphasic calcium phosphate (BCP) cement, consisting of an α-TCP-TTCP as the only solid phase and a calcium phosphate solution (Ca-P soln) as the liquid phase, was recently reported6, 7) . The powder phase of BCP consists of a single solid-solution compound with a monomodal size distribution. The compound is synthesized in a single manufacturing process, and ground to a mono-modal size distribution. This technology not only saves time and manufacturing costs, but also make it easier for regulatory agencies to validate the quality, assuring reproducible clinical outcome. The BCP cement provided good handling properties and desired hardening time, and it set to a sufficiently high strength for clinical use. In addition, during the setting reaction proceeded, the BCP cement mostly converted to hydroxyapatite (HA) as the fi nal product, the main inorganic component of bone, within 24 hours of mixing [6] [7] [8] [9] [10] [11] [12] [13] . The purpose of this study was to determine the histological aspects of BCP cement compared with those of a commercial bone graft material when used for repairing artifi cially created critical bone defects (5mm in diameter) in the calvaria of rats.
Materials and Methods
Materials used in this study are shown in Table 1 . The powder phase of BCP cement was a solid-solution of α-TCP-TTCP, and was prepared by heating a mixture of dicalcium phosphate anhydrous (DCPA) and calcium carbonate (CaCO 3 ) in a furnace, and ground to a mono-modal size distribution with median particle size of 9.96μm. Solid-solutions with compositions ranging from 95% α-TCP/5% TTCP to 5% α-TCP/95% TTCP are contemplated. In general, the corresponding molar Ca/P ratios of the powder range from 1.52 to 1.97, and a Ca/P ratio of 1.8 was used in this study. The scheme and the distribution of BCP powder particle are shown in Fig.1 . The liquid phase of BCP cement consisted of an acidic Ca-P soln (pH2.1), which was produced by mixing phosphoric acid with CaCO 3 and diluted 3.0-fold, 3.5-fold and 4.0-fold with H 2 O, and then used as the cement liquid.
Additionally, tri-sodium citrate anhydrous (Na 3 Cit) in the powder phase and polyvinylpyrrolidone-k25 (PVP-k25) in the liquid phase were included as a water reducing agent and a washout resistance enhancer, respectively [6] [7] [8] [9] [10] [11] [12] [13] . The samples were prepared by mixing BCP (Ca/P=1.8) powder with the cement liquid at a P/L ratio of 3.0. The components and the setting reaction of the BCP cement are shown in Fig. 2 . The total amount of Na 3 Cit in the sample was adjusted to 1.5 mol/L. Na 3 Cit achieved high zeta-potentials of apatite cement caused by adsorption of multiple charged citrate ions at the solid-liquid interface, enabling the eff ective dispersion of cement particles 14) . Using the Na 3 Cit solution decreased the viscosity, achieved injectability, and improved the strength of the cement paste when used as a bone graft materia l8-14) . In this study, the powder contained Na 3 Cit and each liquid contained 0.75wt% of PVP-k25. 4 Taihei Chemical Industrial Co. Ltd., Osaka, Japan α-Tricalcium Phosphate (α-TCP): Ca 3 (PO 4 ) 2 Taihei Chemical Industrial Co. Ltd., Osaka, Japan Trisodium Citrate Anhydrous (Na 3 Cit): Na 3 (C 3 H 5 O(COO) 3 ) Wako Pure Chemical Industries, Ltd., Osaka, Japan Calcium Carbonate: CaCO 3 Wako Pure Chemical Industries, Ltd., Osaka, Japan Liquid phase :
Polyvinylpyrrolidone-k25 (PVP-k25): (C 6 H 9 NO) n BASF Japan Ltd., Tokyo, Japan Phosphoric Acid: H 3 PO 4 Wako Pure Chemical Industries, Ltd., Osaka, Japan Calcium Carbonate: CaCO 3 Wako Pure Chemical Industries, Ltd., Osaka, Japan Sterile Purifi ed Water: H 2 O Nichi-Iko Pharmaceutical Co., Ltd. Components and setting reaction of the BCP cement Three kinds of Ca-P soln., diluted 3.0-fold, 3.5-fold and 4.0-fold with H 2 O, were used as the cement liquid. Na 3 Cit in the powder phase and PVP-k25 in the liquid phase were included as a water reducing agent and a washout resistance enhancer, respectively. During the setting reaction proceeded, the BCP cement mostly converted to HA as the fi nal product.
•
• Preliminary experiments showed that the 3.5-fold Ca-P soln as the cement liquid and mixed at P/L ratio of 3.0 [6] [7] [8] [9] gave the desired physical properties, such as hardening time, compressive strength, HA conversion or clinical applicability. A commercially available calcium phosphate cement, Biopex-R (Hoya Technosurgical Co., Tokyo, Japan), was used as a positive control. According to the product description, the powder phase was composed of α-TCP, TTCP, sodium hydrogen phosphate, HA and magnesium phosphate, and the liquid phase was composed of chondroitin sulfate sodium, disodium succinate, sodium hydrogen sulfi te and water for injection. The control cement was mixed as following to the instructions. A defect with no fi lling material was used as a negative control.
Experimental procedures of this study are shown in Fig. 3 . The study was permitted by the Animal Experimentation Committee at Nihon University School of Dentistry, and performed in the animal and cell culture laboratories at the Nihon University School of Dentistry. The experiments followed the "Guidelines for Animal Experimentation Committee at Nihon University School of Dentistry (AD14D015)". Each experimental material was tested in 9 weeks old male Fischer rats with an average body weight of 150 to 200g. All experimental procedures on given animals were completed as aseptic as possible. The animals were pre-medicated by inhalation of isofl urane and then general anesthesia was induced by intraperitoneal injection of a mixture of 0.15 mg/kg dexmedetomidine hydrochloride, 2.0 mg/kg midazolam, and 2.5 mg/kg butorphanol tartrate of body weight. The forehead of each rat was also locally anesthetized with an injection of 0.5 ml of 1:8-diluted lidocaine (Xylocaine, Astra Zeneca K.K., Osaka, Japan). Under the anesthesia, a 2cm incision was made in the sagittal plane across the cranium, and the full thickness fl ap was refl ected to expose the calvarial bone. A standardized circular trans-osseous bone defect, approximately 5mm in diameter, was created on the cranium using a trephine drill bur with saline cooling 15) (Fig. 4-a) . Two bone defects were created in each animal and fi lled with BCP cement (Fig.4-b) , Biopex-R as the control cement or were left unfi lled as negative control. Each fi lling materials was packed to approximately 1.5 µl of the bone carrier and was injected into the defect area, and then the fi lled area was smoothed. The material used in the defects weighed approximately 1.2mg each. After fi lling the defects, the fl ap, including the periosteum, was closed and sutured with 5-0 polyglycolic acid sutures (Opepolix N, Alfressa Pharma Co., Osaka, Japan).
A fl uorescent labeling agent that would be incorporated into newly formed mineralized tissue, was injected into the abdominal cavity. The agent, tetracycline hydrochloride (TC: Wako Pure Chemical Industries Ltd., Osaka, Japan; 30mg/kg of body weight), was administered 1 week before sacrifi ce.
Histological Preparation of the Specimen
Surgically created bone defects were fi lled with the BCP or control cements. At 0, 4 and 8 weeks after surgery, X-ray micro-CT images (R_ mCT2 system, Rigaku Co., Tokyo, Japan) for each surgical site were taken to confi rm chronological changes of the grafted area (GA).
At 8 weeks after surgery, the animals were sacrifi ced, and 5 biopsies including the test materials were obtained for each experimental group. Histological preparation of the specimen was performed as follows. Biopsies were fixed in 10% neutralized-buffered formalin. Half of the specimens were decalcified using 10% EDTA for 10 days and embedded in paraffi n. These decalcifi ed samples were then sectioned through the sagittal plane across the cranium at central position of the defect, and then cut into approximately 8µm sections, and were stained with hematoxylin-eosin (HE) and tartaric acid resistant phosphatase (TRAP). We selected TRAP for the staining since it clearly stained osteoclast which resorbed residual bone (RB) and low crystalline HA and consequently converted to new bone. Histopathological features of each section were observed using an optical microscope (DM6000B, Leica Microsystems GmbH, Wetzlar, Germany).
Half of undecalcified specimens were prepared for fluorescent labelling analysis (FLA) by being embedded in methyl-metacrylate Bone defects (5mm in diameter) were surgically created in calvaria of rats resin, ground to approximately 50 µm in thickness, and then examined using fl uorescent microscopy (BX51-P, Olympus Co., Tokyo, Japan) for the presence and location of labeling agent on newly formed bone (NB). FLA clearly demonstrated the presence of NB at 8 weeks after surgery, since it spontaneously picked up the TC-fl uorescent agent. The amount of NB formed in each surgical site was evaluated quantitatively using NIH image analysis, which is an automated computer-assisted histometric imaging technique, for sections at a 25 × magnifi cation. Measurements of defect closure (DC) were determined by measuring the distance between the defect margin and the ingrowing bone, at each side of the defect. The measurements are expressed as a percentage of the total defect width (Fig. 5 ) [16] [17] [18] . The boundary of original residual bone was determined by superimposing X-ray micro-CT image on the histological image. Histometric recordings from the samples were used to calculate the group mean (± SD). A student's t-test was used to establish statistical signifi cance (p<0.05).
Results
After the surgery, no apparent infection or complications were observed in any group. The results obtained from this study are shown below:
Histological observations Negative control
In histological observation at 8 weeks after surgery, a negative control showed the defect was mostly covered with thin fibrous connective tissues (FCT) (Fig. 6) . The shape of the defect appeared to have collapsed due to the physical pressure from surrounding tissue. A thin layer of newly formed woven bone, which was immature new alveolar bone, was observed in the portion adjacent to the RB. The above results were confi rmed by FLA and micro-CT observations.
Control cement
Histological observation showed that the control cement filled in defects, it exhibited insufficient washout resistance, and also inadequately maintained the original graft shape and volume (Fig.  7) . The GA was covered by relatively dense FCT, and partially NB formation had occurred adjacent to the defect margin of residual bone area (RA). Immature osseous tissues were also found in the GA. TRAP staining exhibited that osteoclasts (OCs), which resorbed RB and grafted material (GM) and led to converting to bone tissues, were scattered throughout the GM adjacent to RB. The GM did not completely unify with RB surface. In FLA, the fluorescent band corresponding to NB formation in the GA was almost the same as the results obtained in histological observations. These results were also identifi ed by micro-CT observations, which also showed that the GM fi lling the defect did not adequately maintain the original graft shape and volume at 8 weeks after the surgery.
BCP cements
In general, all of the BCP cements showed good adaptability to the defect (Figs. 8-10 ). The cement also exhibited excellent washout resistance and maintained the original graft shape and volume. The GA was nearly completely closed with NB. NB was also observed above and under the GM where it attached the periosteum and subperiosteum. NB that formed under the GM was obviously thicker and more lamellar compared to that which formed above the GM. Some sections showed that osseous tissues extended into the GM. TRAP showed that the GM was apparently resorbed by OC and converted to NB. Natural lamellar bone was clearly found in the GA. Histological features exhibited that no apparent difference existed among 3.0-fold, 3.5-fold and 4.0-fold of BCP cements. According to FLA, NB formations were also showed above and under the GM, especially near the RB. These results were also confi rmed by micro-CT observations. The micro-CT images also showed that BCP cements adequately maintained the original graft shape. The control cement fi lled in defects, it exhibited insuffi cient washout resistance, and also inadequately maintained the original graft shape and volume. GA was covered by relatively dense FCT, and partially NB formation had occurred adjacent to the defect margin of RA. TRAP staining exhibited that OCs were scattered throughout the material adjacent to RB. In FLA, the fl uorescent band corresponding to NB formation in the graft area was almost the same as the results obtained in histological observations. These results were also identifi ed by micro-CT observations. The cement showed good adaptability to the defect. The cement also exhibited excellent washout resistance, and maintained the original graft shape and volume. The GA was nearly completely closed by NB. NB was also observed above and under the GM where it attached the periosteum and subperiosteum. The results observed in the section were almost same as other BCP cements. In general, the area of NB observed in the GA showed slightly larger compared to that observed in GA fi lled with other BCP cements. The results observed in the section were almost same as other BCP cements. In general, the area of NB observed in the GA showed slightly smaller compared to that observed in GA fi lled with other BCP cements.
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All BCP cements showed obviously larger calcifi ed area, where the GM with NB, compared to the original GA. The calcifi ed area of BCP cements was obviously larger than that of the control cement at 8 weeks after surgery.
Histometric NIH image analysis
The DC rates were, for the negative control (7.4%±5.2), the control cement (75.3%±11.7), and BCP cements (1:3-fold dilution=97.2%±5.6, 1:3.5-fold=98.1%±3.2, 1:4.0-fold=95%±8.6) respectively ( Table 2 ). The negative control showed slight NB formation. The control cement showed that NB formed more than half of the filled area. The defect filled with BCP cements was almost completely covered with newly formed bone.
A student's t-test revealed that each value of BCP cements showed no apparent diff erence among them. The DC rates of the BCP cement and the control cement showed significantly larger than that of the negative control (p<0.05). The rate of each BCP cement also exhibited apparently larger than that of the control cement (p<0.05). The above results indicated that BCP cement generally showed faster bone formation and replacement than the control cement.
Discussion
Previous studies [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] have reported that conventional CPCs were excellent materials for use in reconstructive surgery of alveolar bone defects, such as periodontal bone defects and dental implant surgery, because most CPCs form low crystalline HA which is the main inorganic component of bone. On the other hand, CPCs still had some diffi culties in maintaining the original grafted shape at the defect site, because the washout resistance and the viscosity in the body fl uid were insuffi cient 6, 7, [10] [11] [12] [13] 29, 30) . Most conventional CPCs also had fl ows in their hardening and formation of HA. Some commercially available CPCs had poor hardening times and showed inadequate physical properties for clinical use, even 24 hours after mixing. Even if CPCs could be used for bone generated from endochondral ossification, such as tubular bone, vertebrae bone or pelvic bone, most could not be used for intramembranous ossifi cation, such as cranial bone, cheek bone or collar bone. This is because the material did not have suffi cient physical properties and shape integrity when applied to the defects. Some conventional CPCs were also slow to convert to natural bone by the remodeling system of basic multicellular units (BMU), consisting of OCs, osteoblasts, and their assembly.
As a response to the above reasons, it was developed the BCP cements with improved physical properties and usability compared to the conventional CPCs 6, 7) . Before this study, physical properties, such as diametral tensile strength, compressive strength, hardening time, and handling properties, such as injectability, moldability and washout resistance, were examined [6] [7] [8] [9] . The BCP cement showed excellent handling properties after mixing and showed superior washout resistance when immersed in water and physiological-like solution. The cement also had suffi cient physical properties and handling time for clinical use and hardened rapidly in 7 to 10 minutes 8, 9) . Most commercialized CPCs, fi lled in defects but did not adequately maintain the original graft shape, and also had insufficient washout resistance and lost the original graft volume. This should be due to physical fl ow and chemical dissolution of the material components into bodily fl uid.
The bone defects created in this study were a critical size that could not completely close and heal spontaneously. The BCP cement showed excellent washout resistance and sufficiently maintained the original graft shape due to the components and hardening mechanism of the material. All defects filled with the BCP cements showed that the GA was nearly completely covered by NB. The NB formation of BCP cements showed faster bone replacement than that of the control cement. These results suggested that the BCP cement should have excellent shape integrity and washout resistance, and also have superior osteoconductivity and bone replacement properties. The BCP cement showed NB was formed entirely above and under the material where the material attached to the periosteum and subperiosteum. NB that formed under the material was slightly thicker than that formed on the above-side, possibly due to diff erences in blood circulation.
Our previous studies reported that the BCP cement mostly converted to HA as the fi nal product within 24 hours after mixing [6] [7] [8] [9] . HA crystals formed from the BCP cement had low-crystallinity and were nanometerscale crystals similar to those found in bone. Here, we assume that the HA crystals could be easily resorbed by OC and converted to natural bone, which spontaneously occurred in bone remodeling. The BCP cement in the defect sites, mostly consisting of HA, fi rmly combined with RB due to the inorganic component of bone being made from the same material. Therefore, the cement fi lled in the defect and anchored tightly to the surface of RB which, in turn, increased the mechanical strength of the filling material and reduced its susceptibility to infections. The histological study of TRAP staining also showed that OC resorbed the BCP cement, should already have changed to HA, and gradually converted to natural bone. Therefore, we assumed that the GM of BCP cements, mostly consisting of low crystalline HA, should be resorbed by OC and rapidly converted to NB.
In this study, histometoric measurements were performed using NIH image analysis. The DC rates of all BCP cements were over 95%, and the distribution of each data was not wide-spreading. Similar statistical tendency results were also shown in former studies [16] [17] [18] that exhibited the DC rates using osteoinducible materials in rat calvarial defect model. The rate of the BCP cement was apparently larger than that of the control cement. The BCP and control cements were gradually resorbed by OC and converted to natural bone. However, the BCP cement consistently exhibited obviously faster (p<0.05) bone replacement than the control cement. These results suggested that the all the BCP cements should have excellent biocompatibility and osteoconductivity. Micro-CT results showed the cement maintained its original graft shape and adaptability through the entire experimental period, and also exhibited excellent washout resistance to bodily fl uid when applied to bone defects. The results indicated that the BCP cement was successfully retained and had suffi cient physical properties after the fi lling.
The control cement is a commercially prevalent and adequate material for clinical use already, so it is expected that the BCP cement also should be an eff ective and suitable material for bone defects. Control cement 75.3±11.7 * BCP cement: 3.0-fold 97.2±5.6 *# BCP cement: 3.5-fold 98.1±3.2 *# BCP cement: 4.0-fold 95.0±8.6 *# Datas are expressed as means±SD (n=5) * Statistically signifi cant diff erence compared to the negative control (p<0.05) # Statistically apparent diff erence compared to the control cement (p<0.05) Table 2 . Defect closure (%) The DC rates of the BCP cement and the control cement showed signifi cantly larger than that of the negative control (p<0.05). The rate of each BCP cement exhibited apparently larger than that of the control cement (p<0.05).
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